Getinge continues to strengthen its presence in the cardiovascular market, through the acquisition of Datascope Corp

Getinge continues to strengthen its presence in the cardiovascular market,
through the acquisition of Datascope Corp

• Getinge agrees to acquire Datascope, a worldwide leader in counterpulsation
therapy

• Getinge to pay $53 per share in cash, representing 34% premium to Datascope's
volume weighted trading price prior to its June 4th announcement to seek
strategic alternatives for the company

• Datascope's businesses meaningfully expand Getinge's cardiovascular business
worldwide, reinforcing the company's focus on both cardiac surgery and vascular
interventions

• The transaction is expected to be earnings accretive by 2010

Getinge AB, (STO:GETIB) a global medical technology company with, among other,
operations in the cardiac surgery and vascular surgery markets, announced that
it has agreed to acquire Datascope Corp. (NASDAQ: DSCP), a leader in the
cardiovascular market, predominantly in the area of cardiac assist and vascular
surgery, for $53.00 per share, or an aggregate equity value of $865 million in
cash.  Adjusting for Datascope's net cash position of $247 million (net of
estimated tax liabilities related to recent divestitures), the total enterprise
value is $618 million, which implies an EBITDA multiple of 12.9x, based on
2007/08 EBITDA of $48 million.  The offer price represents a premium of 33.6% to
Datascope's volume weighted average price of $39.67 for the three-month period
ended June 3, 2008 (“Reference Share Price”), the day before the Board of
Directors of Datascope announced that it was exploring strategic options for the
company.  The Board of Directors of Datascope has unanimously approved the
transaction and will recommend the offer to Datascope's shareholders. 

Strategic Rationale
Getinge is a leading medical technology company with existing operations in the
cardiac and vascular surgery markets.  Getinge has previously stated its desire
to build its Cardiovascular division into a world leading business with a focus
on cardiac surgery, vascular intervention and cardiac assist.  The acquisition
of Datascope is an important step in this direction and represents a very strong
addition to Getinge's product portfolio as well as its sales organisation.  Pro
forma, Getinge's cardiovascular division generates sales in excess of $650
million, after the acquisition of Datascope.

Synergies
Getinge management expects significant synergies from this transaction,
principally from a revenue perspective.  Synergies will come both from product
and geographic cross selling opportunities.  Datascope also provides Getinge
with access to the interventional cardiology market which is expected to
significantly support the launch of Getinge's new cardiac assist product;
Cardiohelp.  Datascope's vascular surgery business has a number of exciting
products in the pipeline, which are complementary to Getinge's current vascular
surgery portfolio.

Transaction Structure and Financial Impact on Getinge
Under the terms of the merger agreement, Getinge will commence a cash tender
offer to acquire all outstanding shares of Datascope's common stock at a price
of $53.00 per share.  Getinge's obligation to consummate the tender offer is
conditional upon the tender of at least a majority of the fully diluted
Datascope shares in the offer, and the satisfaction of regulatory and other
customary closing conditions.  Following completion of the tender offer, any
remaining Datascope shares would be acquired in a merger for $53.00 per share. 

Getinge will finance the transaction using a fully underwritten credit facility
from Skandinaviska Enskilda Banken AB (“SEB”), one of the leading commercial
banks in Europe.  Getinge intends to refinance part of the credit facility
through a new share issue following the closing of the acquisition.  The new
share issue is expected to raise approximately SEK 1.0 billion and is being
guaranteed by Carl Bennet AB, a company owned by Getinge's Chairman and
principal shareholder, Carl Bennet.

The acquisition is expected to contribute to Getinge's earnings per share, after
acquisition related intangible amortization and financings costs, starting in
2010.

Merrill Lynch International acted as financial advisor to Getinge and Lehman
Brothers acted as financial advisor to Datascope. Alston & Bird and Dechert LLP
served as legal advisors to Getinge and Datascope, respectively. 

About Datascope
Datascope operates in the cardiovascular market.  The operation is divided into
two divisions, Cardiac Assist and Intervascular.  For the fiscal year ended June
30, 2008, the company achieved sales of $231 million, an 8% increase over fiscal
year 2007 sales.  2008 EBITDA increased to $48 million or 14% compared to 2007
EBITDA, adjusted for recent divestitures.  The assets of Datascope as of June
30, 2008 totalled approximately $522 million, liabilities amounted to $115
million and equity equalled $407 million.  Based on preliminary estimates total
non-goodwill intangible assets will be approximately $340 million.  As of 30
June, 2008 Datascope had approximately 765 employees. 

Cardiac Assist
Counterpulsation is a tried and tested therapy, which is used to improve the
blood circulation in a patient's coronary arteries.  The therapy is used in
conjunction with both surgical interventions and cardiology procedures.  The
products which are used in counterpulsation therapy are Intra Aortic Baloon
Pumps (IABP) and balloon catheters where the disposable balloon catheter is
inserted percutaneously into the patient's thoracic aorta.  Datascope has been
the leader of this market since the 1970s.  In the latest fiscal year, IABP
products accounted for 75% of Datascope's total sales.  72% of revenues from the
Cardiac Assist division consist of single use catheters, services and other
disposables.  The Cardiac Assist division also offers an innovative and rapidly
growing hemostasis product to stop bleeding after catheterization.

Intervascular
Datascope's Intervascular division designs, manufactures and distributes
products for vascular surgery and endovascular interventions.  Importantly,
Datascope's intervascular product portfolio expands Getinge's product offering
into the rapidly growing peripheral vascular stent market.  

Geographical Footprint
Manufacturing and product development for Cardiac Assist products are located in
Fairfield and Mahwah, New Jersey.  Vascular products are manufactured and
developed in La Ciotat, France. 

Of Datascope's total sales, c.43% is sold in North America, c.40% in EMEA and
c.17% in the rest of the world.  Datascope sells directly through own sales
companies in USA, Canada, UK, France, Germany, Benelux, Spain, Italy and Japan. 
The company also has a well developed network of agents and distributors.


A telephone conference with Johan Malmquist, CEO, and Ulf Grunander, CFO, will
be held on September 16 at 09.30 CET. 

To participate in the telephone conference, please dial: 

Swedish dial in number: + 46 (0)8 506 269 30 
UK dial in number: + 44 (0)207 108 63 03

09.15 Call in to the conference 
09.30 Presentation and questions & answers 

During the telephone conference a presentation will be held. To access the
presentation
please use this link:
https://www.anywhereconference.com/?Conference=108224080&PIN=616406

The presentation is also available on http://www.getingegroup.com

A recorded version of the conference can be accessed for 5 working days on
following number: 

SE: +46 (0)8 506 269 49, code 224080#

Welcome!



The information provided herin is such that Getinge AB can be obligated to
disclose pursuant to the Securities and Clearing Operations Act and/or the
Financial Instruments Trading Act.